A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation
- Focus Adverse reactions
- Acronyms RASMET
- Sponsors Enterin
- 15 May 2017 According to an Enterin media release, First Patient has been enrolled.
- 15 May 2017 Status changed from not yet recruiting to recruiting, according to an Enterin media release.
- 15 Feb 2017 New trial record